Certara, Inc.

Certara, Inc.

CERTNYSE / NASDAQHealthcareSmall cap

$10.55-$0.13 (-1.2%)

Last close · Data as of Nov 20, 2026

Market cap
$872.7M
P/E
-547.2x
EV / EBITDA
9.7x
Revenue
$418.8M
Net margin
-0.4%
ROCE
1.5%

+31.4% over the last year

Certara, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+7.8%
3M
+20.8%
6M
+125.9%
1Y
+31.4%
5Y
-65.4%

52-week range

Day change -$0.13 (-1.2%) from $10.68 to $10.55 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in CERT, bought on each weekday since 2021.

News & filings

What Certara filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 1.6 million US dollars in fiscal 2025.

Strengths (1)

  • EBITDA grew 41.7% in fiscal 2025, 32.9 points more than revenue.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific.

Read moreShow less

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Sector
Healthcare
Shares outstanding
159.1M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$872.7M
P/E
-547.2x
P/B
0.8x
EV / EBITDA
9.7x
EV / Sales
2.4x
P/S
2.1x
52-week high
$12.22
52-week low
$4.48

Profitability

Operating margin
5.0%
Net margin
-0.4%
EBITDA margin
24.5%
ROE
-0.2%
ROCE
1.5%
ROA
-0.1%
Asset turnover
0.27

Growth

Revenue
$418.8M
Revenue growth, 1Y
8.7%
Revenue CAGR, 3Y
7.7%
Net profit growth, 1Y
-86.8%
Free cash flow
$69.8M

Solvency

Current ratio
2.05
Debt / Equity
0.29
Debt / Assets
0.20
CFO / Net profit
-60.39
Cash / Market cap
21.7%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$418.8M
Cost of revenue$161.1M
Gross profit$257.7M
Operating expenses$236.7M
Research and development$41.0M
Selling, general and administrative$139.1M
Operating income$21.0M
Interest and other-$13.4M
Pretax income$7.6M
Tax and other$9.2M
Net income-$1.6M

Revenue and net profit

Revenue grew 8.7% in FY2025; net profit is the dashed line.

Certara, Inc. revenue and net profit by fiscal year
Certara, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$335.6M$14.7M
FY2023$354.3M-$55.4M
FY2024$385.1M-$12.1M
FY2025$418.8M-$1.6M

Cash flows

FY2025: $96.3M from operations, $69.8M free after investment (dashed).

Certara, Inc. operating and free cash flow by fiscal year
Certara, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$92.5M$80.0M
FY2023$82.8M$67.4M
FY2024$80.5M$59.4M
FY2025$96.3M$69.8M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$418.8M+8.7%1Y
EBITDA
$102.5M+41.7%1Y
Net profit
-$1.6M
Cash from operations
$96.3M+19.7%1Y
Free cash flow
$69.8M+17.4%1Y
Revenue CAGR, 3Y
7.7%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$418.8M$102.5M-$1.6M$69.8M-0.2%+8.7%-86.8%

Monthly returns

Month-by-month returns of CERT across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.6B
Liabilities$493.8M
Equity$1.1B
Paid-in capital$1.3B
Retained earnings-$129.9M
Treasury stock$66.7M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; CERT highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Certara, Inc. (this company)2.4x

Not shown (no positive earnings and no EV / Sales): Annexon, Inc., Cullinan Therapeutics, Inc., Jade Biosciences, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Certara, Inc.CERTthis company$872.7M-547.2x0.8x-0.2%9.7x
Annexon, Inc.ANNX$892.9M-4.3x4.2x-97.7%-3.5x
Pacira BioSciences, Inc.PCRX$892.0M126.9x1.3x1.0%8.7x
Xencor, Inc.XNCR$890.4M—1.4x-14.5%—
Cullinan Therapeutics, Inc.CGEM$886.8M-4.0x2.2x-53.8%-3.3x
MeiraGTx Holdings plcMGTX$886.3M-7.8x-153.0x1971.4%-10.2x
Jade Biosciences, Inc.JBIO$875.6M—-18.7x-38.3%—
Talkspace, Inc.TALK$871.1M111.8x7.4x6.7%129.1x
Arbutus Biopharma CorporationABUS$859.3M-25.6x11.2x-43.7%-25.5x
Peer median—-4.2x1.8x-26.4%-3.4x

Year-to-date ROI

CERT since 1 January, against earlier years.

Historical volatility

CERT's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Certara, Inc. operating margin by fiscal year
Certara, Inc. operating margin by fiscal year
DateOperating margin
FY20229.7%
FY20231.8%
FY2024-0.4%
FY20255.0%
LineFY2025
Cost of revenueCost Of Revenue$161.1M
Gross profitGross Profit$257.7M
Operating expensesOperating Expense$236.7M
Research and developmentResearch And Development$41.0M
Depreciation and amortisationDepreciation And Amortization In Income Statement$56.6M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$56.6M
Depreciation income statementDepreciation Income Statement—
Amortization—
Amortisation of intangiblesAmortization Of Intangibles Income Statement—
Total expensesTotal Expenses$397.8M
Pretax incomePretax Income$7.6M

Learn while you research

Academy chapters picked for Certara, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →